Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00559767 · ClinicalTrials.gov registry record

Mapping of End Stage Renal Disease Genetic Susceptibility in African Americans by Admixture Linkage Disequilibrium

A clinical trial, sponsored by National Cancer Institute (NCI).

Completed
Registry status
2,860
Enrollment target

NCT00559767: Completed study, sponsored by National Cancer Institute (NCI).

NCT00559767 is a clinical trial that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 2,860 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT00559767 has completed, sponsored by National Cancer Institute (NCI).

COMPLETED
Registry status
2,860 participants
Enrollment target

Study Summary

This study will identify which regions on the genes, and genes themselves, may account for an increased risk of end stage renal disease (ESRD), that is, near-total loss of kidney function, for people of African American descent. Researchers will use a technique called admixture linkage disequilibrium (MALD) to study genomes, genetic material, in about 2,500 participants from two existing studies and participants who will serve as controls. ESRD disproportionately affects African Americans, who constitute 29% of all ESRD patients in the Medicare ESRD program. The disease can result from a variety of diseases, with diabetes as the leading underlying cause (44% of cases) and hypertension as the second leading cause (26%). The proportion of ESRD cases caused by diabetes has increased dramatically. Patients age 18 and older who are African American, who have ESRD, and who are participants of the FIND and CHOICE studies may be eligible for this study. FIND, or Family Investigation of Diabetes and Nephropathy, involves a multicenter study to identify susceptibility genes, that is, those with a risk, for diabetic and other forms of kidney disease. CHOICE, or Choices for Healthy Outcomes in Caring for ESRD patients is an ongoing study that identifies risk factors for cardiovascular outcomes in ESRD patients. The principle of mapping by MALD involves genetic variations that exist across populations. When mixing occurs between populations having different (heterogeneous) genes, the admixed offspring inherits chromosomes of distinct ancestry. However, over generations of mating, and recombination over several generations, originally large blocks of DNA from African ancestry have become part of smaller segments throughout the chromosome. The study will focus on risk alleles, that is, alternative forms of genes that carry a disease risk. Risk alleles are closely related to nearby ancestral gene markers found in a person. Patients will undergo a collection of blood and urine for

Trial Details

FieldValue
Enrollment Target 2,860 participants
Start Date 2006-06-30
Est. Completion 2012-04-10
National Cancer Institute (NCI)

3,257 total trials

What the finished NCT00559767 record still lists

NCT00559767 is an observational study that tracks outcomes without assigning an intervention. Its 2,860 participants enrollment target places it among the larger protocols in the corpus.

The record links to 0 conditions, and to 0 interventions.

NCT00559767 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00559767 about?

NCT00559767 is a clinical study titled "Mapping of End Stage Renal Disease Genetic Susceptibility in African Americans by Admixture Linkage Disequilibrium". This study will identify which regions on the genes, and genes themselves, may account for an increased risk of end stage renal disease (ESRD), that is, near-total loss of kidney function, for people of African American descent. Researchers will use a technique called admixture linkage disequilibriu...

What is the current status of trial NCT00559767?

This trial is currently completed. The enrollment target is 2,860 participants. The study started on 2006-06-30. Estimated completion is 2012-04-10.

Who is sponsoring clinical trial NCT00559767?

This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT06351085 · 2,869 participants · NA

    Enhancing Lung Cancer Screening Through Human-Centered Intervention

  • NCT05624450 · 2,870 participants · Phase 3

    Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen

  • NCT06150781 · 2,842 participants

    Aimovig Pregnancy Exposure Registry

  • NCT06273436 · 2,894 participants · NA

    Healing, Equity, Advocacy and Respect for Mamas

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT00559767, the US trial registry maintained by the National Library of Medicine. NCT00559767 (large enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.